How does the agreement with Genentech work? It says on the site they are entitled to like 115 million and they have received like 18 million and I saw the single digit share percentages. I am trying to figure out when will CRIS make real money because I really like the products they wanted to keep and wonder if it maybe quite a while. This kinda reminds me of Medarex great products and one of the best pipelines in the world but was given away because they had agreements everywhere and could not make any money.
I think that CURIS should renegotiate the royalty terms. It is one of the lowest in the history of biotech agreements. This is how the big pharma is destroying the research while cutting their own scientific staff. Not good for anyone!
My advice to you is to study their cudc 907 pi3k + hdac molecule. It just went into trial. Compare INFI and MEIP. Their runups are due to HDAC for meip and pi3k delta for blood cancers. Look at their 1 year charts and follow the pattern. Also the IAP drug which will have data presented at asco in june.
I agree, with HDAC inhibitors and they are just getting started and not to late to the game. Those and adenovirus agents are going to be interesting in the oncology. I think inflammation is a huge issue for most diseases infact from muscle, fibro issues to diabetes, cancer and other. That is the reason I believe that CRIS is a good slow boat to China pick and buy some each month and you will be surprised the products that they own could be very good products if not they probably sell out for very little. I was not impressed with royalty from Genentech on hedghog that was a steal it seems.